GSK acquires RAPT for $2.2 billion to enhance allergy treatment portfolio
RAPT Therapeutics, based in San Francisco, has been developing therapies aimed at addressing the growing prevalence of food allergies, which affect millions globally. The company’s lead candidate, a drug designed to treat peanut allergies, has shown promising results in clinical trials, making it an attractive target for GSK as it seeks to enhance its offerings … Read more